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Background: Mutations in the CDKN2A and CDK4 genes predispose to melanoma. From three case-control studies
of cutaneous melanoma, we estimated the prevalence and predictors of these mutations for people from regions
with widely differing latitudes and melanoma incidence.
Methods: Population-based cases and controls from the United Kingdom (1586 cases, 499 controls) and Australia
(596 early-onset cases, 476 controls), and a hospital-based series from Spain (747 cases, 109 controls), were screened
for variants in all exons of CDKN2A and the p16INK4A binding domain of CDK4.
Results: The prevalence of mutations for people with melanoma was similar across regions: 2.3%, 2.5% and 2.0%
for Australia, Spain and the United Kingdom respectively. The strongest predictors of carrying a mutation were
having multiple primaries (odds ratio (OR) = 5.4, 95% confidence interval (CI: 2.5, 11.6) for 2 primaries and OR = 32.4
(95% CI: 14.7, 71.2) for 3 or more compared with 1 primary only); and family history (OR = 3.8; 95% CI:1.89, 7.5) for 1
affected first- or second-degree relative and OR = 23.2 (95% CI: 11.3, 47.6) for 2 or more compared with no affected
relatives). Only 1.1% of melanoma cases with neither a family history nor multiple primaries had mutations.
Conclusions: There is a low probability (<2%) of detecting a germline CDKN2A mutation in people with melanoma
except for those with a strong family history of melanoma (≥2 affected relatives, 25%), three or more primary
melanomas (29%), or more than one primary melanoma who also have other affected relatives (27%).
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Cutaneous malignant melanoma is responsible for most
skin cancer mortality worldwide and continues to increase
in incidence in the most susceptible populations [1,2].
The principal high-penetrance susceptibility gene iden-
tified as pathogenic to date is the CDKN2A locus on
chromosome 9 [3]. Additionally, a small number of
melanoma pedigrees have been found to carry mutations* Correspondence: m.harland@leeds.ac.uk
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unless otherwise stated.of the CDK4 gene, at the binding site for the CDKN2A
gene product [4,5]. For members of families with multiple
cases of melanoma, the presence of relatives with multiple
primary melanoma (MPM), pancreatic cancer, and early
age at onset predict the presence of germline CDKN2A
mutations [6-9]. The predictors of mutation status for
melanoma cases who have not been selected for family
history or MPM are much less well understood.
There are only limited data available on the prevalence of
CDKN2A and CDK4 mutations outside the context of fa-
milial melanoma. Some small, early studies have reportedl Ltd. This is an Open Access article distributed under the terms of the Creative
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population-based Norwegian study of MPM cases re-
ported a mutation prevalence of 21.0% for familial cases
and 3.2% for the non-familial cases [11]. A large, inter-
national, population-based study recruiting from a range
of latitudes reported a mutation prevalence of 1.2% for
cases with a single primary melanoma and 2.9% for MPM
cases [12]. Previous studies have suggested that in
Mediterranean countries and Latin American countries
with a relatively low incidence of melanoma, the propor-
tion of cases in the population with germline mutations
might be higher [13,14]. Early age at onset in the absence
of a family history might only be a weak predictor of
CDKN2A mutations, which notably are rare in childhood
and adolescent melanoma (1.4% of cases in one study) [15].
We report here the prevalence and predictors of carry-
ing a pathogenic CDKN2A or CDK4 exon 2 mutation
for three populations, UK, Spain and Australia, with dif-
ferent phenotypes (Mediterranean compared with North
European), living at very different latitudes (from 37°
south to 53° north), and for cases with a wide range of
age at diagnosis and family history. We have previously
reported that the penetrance of CDKN2A mutations in
population-ascertained families is similar in the UK and
Australia; mutation carriers appeared to have the same
cumulative risk of melanoma irrespective of ambient UV
irradiance [16]. We hypothesized that the prevalence of
germline mutations would be: 1) higher for melanoma
cases living in a country with lower levels of sun expo-
sure (UK) than for melanoma cases of a similar ethnicity
living in a country with much higher levels of sun expos-
ure (Australia); 2) higher for cases with MPM and a fam-
ily history than for those without; and 3) higher for
early-onset cases than for late-onset cases. We also re-
port the prevalence of non-coding variants (p.A148T
and the 3′UTR variants) of CDKN2A.
Methods
Samples and subjects
The frequency of germline CDKN2A and CDK4 muta-
tions was investigated using population-based series of
melanoma cases and population-ascertained controls
from Leeds, United Kingdom (previously described [17])
and Australian cities (Brisbane, Sydney and Melbourne)
in the Australian Melanoma Family Study [18]. A third
cohort of cases and controls was ascertained through
the Melanoma Unit in the Hospital Clinic of Barcelona,
Spain.
In the UK, population-ascertained incident pathologic-
ally confirmed melanoma cases have been recruited to a
case-control study since 2000 in a geographically defined
area of Yorkshire and the Northern region of the UK
(67% case participation). Only cases with invasive lesions
were recruited. 2085 male and female people (agedbetween 18 and 82 years) were diagnosed in the period
from September 2000 to September 2011. Here we re-
port on the first 1586 cases for which germline DNA
was screened. The cases were identified through clini-
cians, pathology registers and the cancer registry to en-
sure maximal ascertainment. Between September 2000
and June 2003 all people with invasive melanoma were
invited to participate. From July 2003 to September
2011, cases with Breslow thickness less than 0.75 mm
were not invited in order to enrich the cohort to observe
clinical outcomes. 513 population-ascertained controls
were identified from the cases’ family doctors; 55% of
controls who expressed an interest in participation did
so. The first 499 of the UK population-based controls
were screened in this study. Cases and controls were
asked about family history of melanoma and previous
melanomas. Analyses of family history for this manu-
script were based on self-report.
In Australia, 629 people with histopathologically-
confirmed first primary invasive melanoma diagnosed at
ages 18-39 years in the greater urban areas of Brisbane,
Sydney and Melbourne were ascertained between 1st July
2000 and 31st Dec 2002, together with their first- and
second-degree relatives. Those with a previous invasive
melanoma were not eligible, but 15 who presented with
synchronous primary melanomas or a previous in situ pri-
mary melanoma remained eligible; participation was 54%
of those eligible and 76% of those contactable. Population-
based, age-city-sex-matched controls (n = 240) were ascer-
tained from the electoral roll for each state (participation
was 23% of those eligible and 42% of those contactable),
and 295 spouse/friend controls (80% of those nominated
participated and there was a spouse/friend control for 47%
of cases). The population and spouse/friend control groups
were similar in demographic detail, ancestry and preva-
lence of a reported family history of melanoma, and so
were combined for this analysis. All those with blood sam-
ples (n = 596 cases and 476 controls) were screened for
mutations.
The recruits from Barcelona, Spain, were identified
from a clinic-based series. The Melanoma Unit at the
Hospital Clinic in Barcelona manages 36% of all mela-
noma cases presenting to hospitals in Catalonia; a popu-
lation of 7 million inhabitants with ~710 new cases of
melanoma per year in the last 5 years (registry of the
Xarxa Catalana de Melanoma). All cases with a diagnosis
of at least one melanoma and with available DNA were
eligible. Overall participation was 64%. In 2002, during a
period of 2 months, all workers presenting for annual
health review at Lafarge Cementos and Finanzauto, S.A
(a local construction supply company) were invited to
participate as controls; participation was 68%. A total of
747 Spanish cases recruited from June 1999 to January
2004 and 109 controls were screened for mutations.
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tained from all relevant multiregional and local ethics
committees in each country.
Mutation screening
Mutation screening of CDKN2A exons 1α, 1β, 2, 3 and
CDK4 exon 2 was carried out at the core centre of each
study: bidirectional DNA sequencing (CDKN2A exons
1α, 1β, 3 and CDK4 exon 2) and denaturing high per-
formance liquid chromatography (DHPLC) (CDKN2A
exon 2 only) at the Sydney core of the Australian Mela-
noma Family Study; single strand conformation poly-
morphism (SSCP) analysis at Barcelona; and either DHPLC
or high resolution melting curve analysis (HRMCA) at
Leeds. Primers, protocols and reaction conditions were as
previously described for SSCP [13]; DHPLC [19]; and
HRMCA [20,21]. The equivalence of these methods for
identifying mutations has previously been confirmed [19].
Sequencing analysis of SSCP, DHPLC and HRMCA
‘positive’ samples
All amplicons that displayed an aberrant SSCP, DHPLC
or HRMCA profile were bi-directionally sequenced as
previously described [19] to identify the underlying nu-
cleotide change.
Assignment of significance of status to variants
For the purposes of this study the observed variants were
classified as ‘pathogenic’, that is, they are presumed to pre-
dispose to melanoma, or as ‘non-pathogenic’. Variants were
classified according to a flow chart (Additional file 1), using
the following criteria: having functional evidence of
impaired protein function; predicted to result in protein
truncation (via nonsense mutation, frameshift, or altered
splicing); previously reported co-segregation with disease in
large melanoma families; or, if these data were not available,
prediction of a strong deleterious effect on CDKN2A
protein by bioinformatic criteria based on SIFT (http://sift.
jcvi.org/), Polyphen (http://genetics.bwh.harvard.edu/pph/)
or pMut (http://mmb2.pcb.ub.es:8080/PMut/). The com-
mon CDKN2A variant p.A148T (rs3731249) and the
3′ UTR variants c.*29C >G (rs11515) and c.*69C >T
(rs3088440) were classified as pathogenic ‘low penetrance’
variants, based on previous investigations into their possible
association with melanoma [22-26], and were analyzed
separately.
Statistical methods
Cochran-Mantel-Haenszel tests were used to determine
whether the prevalence of mutation differed by mela-
noma status, family history of melanoma, having mul-
tiple primary of melanomas and country. Wilcoxon
signed ranks tests were used to determine whether the
prevalence of pathogenic mutations differed by tumourthickness. Difference in means of quantitative factors, e.g.
age, were assessed by Student’s T Test. Distributions of
qualitative factors were compared across groups using
Fisher’s Exact Test.
Unconditional logistic regression was used to assess
the impact of age at diagnosis, family history of melan-
oma (in first- and second degree relatives: 0, 1, 2 or
more relatives) and the presence of multiple primaries
(1, 2, 3 or more primaries) on the odds of carrying a
pathogenic CDKN2A mutation. Results are reported as
odds ratios (ORs) and 95% confidence intervals (CIs).
We also estimated the crude ORs and 95% CIs for mela-
noma associated with carrying the low penetrance vari-
ants p.A148T, c.*29C > G and c.*69C > T. All analyses
were carried out using SAS version 9.1 (SAS Institute
Inc. Cary, NC, USA), or Stata.
We conducted goodness of fit tests using a multivari-
ate model containing family history, presence of multiple
primaries, age and sex, to examine how well this model
predicted the number of observed mutation carriers in
our study samples from each country.
Results
Analysis of pathogenic CDKN2A mutations
The numbers of cases and controls screened at each
centre, age at diagnosis (cases) or recruitment (controls),
the proportion of cases with a family history of mela-
noma, and the presence of MPM are shown in Table 1.
Information on family history and MPM is based on in-
formation available at the time of recruitment.
A total of 2929 melanoma cases and 1084 controls
were screened for mutations in CDKN2A exons 1α, 1β,
2 and 3 and CDK4 exon 2. No variants were identified
in CDK4 exon 2. Of the 58 CDKN2A variants identified
in this study (Additional file 2) 33 were deemed very
likely to be pathogenic mutations (Table 2 and
Additional file 3). No pathogenic variants were identified
in the control samples. Twelve different pathogenic va-
riants were identified in the Australian cases (14 carriers
of pathogenic mutations out of 596 cases in total), 11 in
the Spanish cases (19 out of 747) and 17 in the UK cases
(31 out of 1586) (Table 2).
The prevalence of pathogenic mutations observed for
melanoma cases at each centre was similar, with an over-
all frequency of 2.2% (95% CI: 1.7, 2.7%) for the three
populations investigated with no evidence of any diffe-
rences across the populations (chi-square test, p = 0.63)
(Table 3).
The prevalence of pathogenic mutations increased
with extent of family history (defined as the number of
affected first or second degree relatives) for each of the
three populations, rising, in the combined dataset, from
1.5% of cases for those without a family history to 5.2%
for those with one affected relative, and to 25.5% for
Table 1 Descriptive characteristics of individuals recruited to studies
Country Australia Spain UK
Case/Control Case Control Case Control Case Control
Number screened 596 476 747 109 1586 499
Age at diagnosis/recruitment1 < 40 (%) 596 (100) 377 (79) 232 (31) 18 (17) 289 (18) 61 (12)
≥ 40 (%) 0 99 (21) 508 (69) 91 (83) 1297 (82) 438 (88)
Affected relatives1,2 0 (%) 500 (83.9) - 690 (93.2) - 1470 (92.7) -
1 (%) 76 (12.8) - 34 (4.6) - 101 (6.3) -
2+ (%) 20 (3.4) - 16 (2.2) - 15 (0.9) -
Number of melanoma primaries1,2 1 581 (97.5) - 639 (86.4) - 1495 (94.3) -
2 14 (2.4) - 80 (10.8) - 73 (4.6) -
3+ 1 (0.1) - 21 (2.8) - 18 (1.1) -
1Age at diagnosis, number of affected relatives and number of melanoma primaries were not available for seven Spanish cases.
2Data on family history were not reported for controls as this information is not relevant to this analysis, and number of primary melanomas was not reported as
no controls had melanoma at recruitment to the study.
Harland et al. Hereditary Cancer in Clinical Practice 2014, 12:20 Page 4 of 10
http://www.hccpjournal.com/content/12/1/20those with two or more affected relatives (Table 4). In
Spain and the UK (combined), there was a correspon-
ding increase with the number of lifetime melanoma pri-
maries rising from 1.3% for cases with only a single
primary to 6.5% for cases with two primaries and 29.3%
for three or more. In Australia, where the eligibility cri-
teria excluded those with a previous invasive melanoma,
2.4% of cases with a single primary at diagnosis had a
mutation while none of the 15 cases with MPM (who
presented with synchronous primary melanomas or a
previous in situ primary melanoma) had a mutation
(Table 4).
Compared with cases without a family history, cases
with one affected first or second degree relative had a
three-fold increased odds of carrying a mutation (OR
3.8; 95% CI: 1.9, 7.5), after adjusting for presence of mul-
tiple primaries, age and country, and for those with two
or more affected relatives the odds of carrying a muta-
tion was further increased (OR 23.2; 95% CI: 11.3, 47.6).
The same trend was apparent for each of the three
countries (Table 4).
For Spain and the UK, there was a significant positive
association between number of primary melanomas
identified in the case and the likelihood of carrying a
pathogenic mutation (Table 4). Overall, compared with
cases with a single primary melanoma, cases with two
primary melanomas had a 5-fold increased odds of car-
rying a mutation (OR 5.4; 95% CI: 2.5, 11.6), after adjus-
ting for family history, age and country; and for those
with three or more primary melanomas the odds of car-
rying a mutation were much higher (OR 32.4; 95% CI:
14.7, 71.2).
The prevalence of mutations also increased for cases
with multiple risk factors (family history plus multiple
primaries). For instance, in Spain, mutation prevalence
was 8.7% for MPM without a family history, 7.1% for
cases with a family history but only one primary, and17.4% for cases with MPM and a family history (data not
shown). A similar pattern was seen for UK cases (7.5%,
5.7% and 45.4%) (data not shown). Table 5 shows, for
the 3 countries combined, the prevalence of CDKN2A
mutations, and the OR for finding a mutation for combi-
nations of risk factors compared with the reference ca-
tegory of no family history and a single primary. For
persons with two or more affected relatives and a per-
sonal history of three or more primary melanomas, the
mutation prevalence was 60% and the OR for finding a
mutation estimated as 146.6 (95% CI: 23.1, 928.1).
Estimation of the expected numbers of cancers based
on a multivariate model considering family history, the
presence of multiple primaries, age, and sex, but un-
adjusted for country of recruitment, showed that this
model predicted the number of observed carriers well
(22.6 expected for Spain (observed = 19), 19.9 expected
for the UK (observed = 22) and 12.5 expected for
Australia (14 observed)) indicating that the predictors of
having a mutation are consistent across populations in-
dependently of the baseline incidence rate or the precise
method of ascertainment.
In Spain, there was a strong association between age
at diagnosis and presence of a mutation, with carriers of
a pathogenic mutation being diagnosed at age 35.9 years
on average compared with 50.1 years for the cases not
found to carry a pathogenic mutation in CDKN2A (p =
0.0002, data not shown). There was no similar asso-
ciation in the Australian (33.9 years vs. 32.7 years, res-
pectively; p = 0.27) and UK samples (51.0 years vs.
53.8 years, respectively; p = 0.26), but the limited age
range of the Australian study precluded further analysis.
Within the Australian and UK samples, there was no
evidence that mutation prevalence differed by gender
(data not shown) but for Spain, 3.9% of male cases were
carriers compared with 1.6% of female cases (p = 0.06
Fisher’s exact test).




p16 nucleotide p16 protein p14 nucleotide p14 protein Australia Spain United Kingdom
5′UTR c.-34G > T r.-34_-32 > p.M1 _ _ 1 1 1
Exon 1α c.9_32del24 p.A4_10Edel7 _ _ . . 3
c.32_33ins9_32 p.M1_S8dup _ _ 1 . 4
c.52_57dup6 p.20T_21Adup _ _ 1 . 1
c.68G > A p.G23D _ _ . . 1
c.71G > C p.R24P _ _ . . 1
c.95T > C p.L32P _ _ 1 . 1
c.104G > A p.G35E _ _ . 1 .
c.104G > C p.G35A _ _ . . 1
c.106delG p.A36RfsX17 _ _ . 1 .
c.113C > G p.P38R _ _ . . 1
Exon 1β _ _ c.45_60dup p.V22PfsX46 . 1 .
_ _ c.81C > G p.I27M 1 . .
_ _ c.102G > A p.W34X 1 . .
_ _ c.193G > A p.G65S 1 . .
_ _ c.193G > C p.G65R 1 . .
Exon 2 c.159G > C p.M53I c.202G > C p.D68H . . 5
c.176T > G p.V59G c.219T > G p.S73R . 3 .
c.188T > C p.L63P c.231T > C p.A77A . . 2
c.194T > C p.L65P c.237T > C p.A79A 1 1 .
c.202_203GC > TT p.A68L c.245_246GC > TT p.R82L 1 . .
c.206A > G p.E69G c.249A > G p.G83G 3 . .
c.212A > C p.N71T c.255A > C p.Q85H . . 1
c.228_246del19 p.L77TfsX62 c.271_289del19 p.R90VfsX75 . . 2
c.240_253del14 p.81PfsX56 c.92_105del14 p.95TfsX56 . . 1
c.251A > C p.D84A c.294A > C p.R84R . . 1
c.259C > T p.R87W c.302C > T p.P101L . 2 .
c.301G > T p.G101W c.344G > T p.R115L . 5 .
c.331G > A p.G111S c.374G > A p.G125E . . 1
c.358delG p.E120SfsX26 _ _ . 1 .
c.370C > T p.R124C _ _ . 2 .
c.379G > T p.A127S _ _ . 1 .
Intron 2 c.458-105A > G p.156_157del _ _ 1 . 4
Total 14 19 31
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cases with melanomas at different body sites (head and
neck; trunk; limbs; other) for Australia and Spain. For the
UK, there was some evidence that cases with tumours on
the trunk were more likely to carry a mutation than cases
with tumours at other sites (Fisher’s exact test p = 0.04,
data not shown). There was also some weak evidence that
thinner tumours were associated with CDKN2A mutations
for the UK samples (p = 0.05, data not shown), but not for
the Australian or Spanish samples. For the UK, 3.3% oftumours with Breslow ≤1 mm had CDKN2A mutations,
compared with 1.2% of those >1 mm.
Analysis of lower penetrance CDKN2A variants
The low penetrance variant p.A148T was observed at an
overall frequency of 7.6% for melanoma cases, and 5.2%
for controls (p = 0.008) (Table 3) (p = 0.17 and 0.57 for
homogeneity of prevalence among controls and cases,
respectively). Crude ORs for risk of melanoma for the
three countries were; Australia: 2.2 (95% CI: 1.3, 3.9);
Table 3 Number and percentage of individuals for whom pathogenic and low penetrance CDKN2A variants were
identified
Variant Australia Spain1 UK Overall
CDKN2A high penetrance mutation present cases 14 (2.3) 19 (2.5) 31 (2.0) 64 (2.2)
controls 0 (0) 0 (0) 0 (0) 0 (0)
wild type cases 582 (97.7) 728 (97.5) 1555 (98.0) 2865 (97.8)
controls 476 (100) 109 (100) 499 (100) 1084 (100)
A148T variant present cases 48 (8.1) 63 (8.4) 110 (6.9) 221 (7.6)
controls 18 (3.8) 6 (5.6) 32 (6.4) 56 (5.2)
wild type cases 548 (91.9) 684 (91.6) 1476 (93.1) 2708 (92.4)
controls 458 (96.2) 102 (94.4) 467 (93.6) 1027 (94.8)
c.*29C > G variant present cases 163 (27.4) 425 (26.9) 588 (27.0)
controls 125 (26.7) 133 (27.4) 258 (26.8)
wild type cases 433 (72.6) 1155 (73.1) 1588 (73.0)
controls 351 (73.7) 352 (72.6) 703 (73.2)
c.*69C > T variant present cases 111 (18.6) 291 (18.4) 402 (18.5)
controls 485 (81.4) 1289 (81.6) 1774 (81.5)
wild type cases 78 (16.4) 98 (20.2) 176 (18.3)
controls 398 (83.6) 387 (79.8) 785 (81.7)
1There were no c.*29C > G or c.*69C > T variant data available for the Spanish sample.
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Analysis of all studies together suggested that presence of
a variant increased melanoma risk (OR 1.5; 95% CI: 1.1,
2.0) (p = 0.009, data not shown). As the Australian cases
were all <40 years of age, we examined whether the posi-
tive finding for Australia related to an effect of age at on-
set. Analysis from the UK supported this suggestion with
ORs of 1.6 (95% CI: 0.7, 3.7) and 0.9 (95% CI: 0.6, 1.5)
within the age groups ≤50 and >50 years respectively,




% OR2 (95% CI) No./total cases % OR
Family
history4
0 7/500 1.4 1.0 13/696 1.9 1.0
1 4/76 5.3 3.9 (1.1, 13.7) 3/35 8.6 4.9 (
2+ 3/20 15.0 12.4 (3.0, 52.3) 3/16 18.8 12.1
No. of
primaries5
1 14/581 2.4 n/a 8/644 1.2 1.0
2 0/14 0 6/80 7.5 6.5 (
3+ 0/1 0 5/23 21.7 22.1
1Number of cases with a pathogenic CDKN2A mutation/the total number of cases.
2Unadjusted odds ratio.
3“Family history” analysis ORs adjusted for presence of MPM, age at diagnosis and c
diagnosis and country.
4Number of first or second degree relatives with melanoma.
5Number of primary melanomas diagnosed in the case. Few MPMs were observedConversely, the Spanish data suggested a stronger asso-
ciation for older onset cases: crude ORs were 0.9 (95%
CI: 0.3, 2.4) for ≤50 years and 4.8 (95% CI: 0.6, 36.1)
for >50 years, but the evidence for a difference was
weak, p = 0.5. The carriage of the p.A148T variant was
not associated with MPM (p = 0.14) or family history
(p = 0.60).
The 3′ UTR variant c.*29C > G was observed at an
overall frequency of 27.0% for cases and 26.8% for con-




% OR (95% CI) % Multivariate OR3
20/1470 1.4 1.0 1.5 1.0
1.3, 18.2) 4/101 4.0 3.0 (1.0, 8.9) 5.2 3.8 (1.9, 7.5)
(3.1, 47.7) 7/15 46.7 63.4 (21.0, 19.8) 25.5 23.2 (11.3, 47.6)
20/1495 1.4 1.0 1.3 1.0
2.2, 19.1) 4/73 5.5 4.3 (1.4, 12.9) 6.5 5.4 (2.5, 11.6)
(6.6, 74.2) 7/18 38.9 46.9 (16.5, 133.5) 29.3 32.4 (14.7, 71.2)
ountry; “Number of primaries” analysis adjusted for family history, sex, age at
for the Australian cases due to the study design.
Table 5 Cross-tabulation of mutation prevalence and odds ratios, according to family history and multiple primaries
No family history One affected relative Two or more affected relatives
Prevalence of CDKN2A pathogenic mutation
One primary only 1.1% (27/2495) 3.8% (7/185) 20.0% (8/40)
Two primaries 3.6% (5/140) 14.3% (3/21) 33.3% (2/6)
Three or more primaries 26.7% (8/30) 20.0% (1/5) 60.0% (3/5)
Odds ratios1 and 95% confidence intervals
One primary only 1 (reference) 3.3 (1.4, 7.7) 18.9 (7.8, 45.5)
Two primaries 3.5 (1.3, 9.3) 13.1 (3.6, 47.8) 42.7 (7.5, 244.0)
Three or more primaries 33.1 (13.5, 81.5) 23.8 (2.6, 221.2) 146.6 (23.1, 928.1)
1Multivariate ORs adjusted for age at diagnosis and country.
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limits of the SSCP screen employed. Crude ORs for risk
of melanoma for Australia and the UK were 1.06 (95%
CI: 0.81, 1.39) and 0.97 (95% CI: 0.77, 1.22) respectively.
The 3′ UTR variant c.*69C > T was observed at an over-
all frequency of 18.5% for cases and 18.3% for controls.
Crude ORs for risk of melanoma for Australia and the
UK were 1.17 (95% CI: 0.85, 1.61) and 0.89 (95% CI:
0.69, 1.15) respectively.
Discussion
We report a large study aimed at characterizing the
prevalence and predictors of pathogenic CDKN2A muta-
tions for melanoma cases. Its strengths include its size
and participant recruitment at very different latitudes so
that the effect of ambient sun exposure might be inferred.
Its main weakness is that differences in case ascertainment
for the three studies may have obscured real differences in
mutation frequency between populations.
We found that population-based melanoma cases re-
cruited at different latitudes had very similar probabi-
lities of carrying a pathogenic mutation of the CDKN2A
gene of 2.0-2.5%. This finding is consistent with that of
the international, population-based GEM study [12].
These findings do not support our hypothesis that the
prevalence of germline mutations would be higher for
melanoma cases in a country with lower levels of sun
exposure (UK) than for one in which melanoma cases
with similar ethnicity (derived largely from UK immi-
gration) live with much higher levels of sun exposure
(Australia).
We do not think that differences in mutation detection
methodology are likely to have obscured any differences
in mutation prevalence between countries, as SSCP,
DHPLC and direct re-sequencing have been shown to
have similar sensitivity and specificity [19]. The classifi-
cation of variants as pathogenic or non-pathogenic is
also vital for a study of this type [27]. Effects on protein
function have not been investigated for many CDKN2A
variants identified by this and other studies. We have
used a range of evidence to classify variants where thereare no available functional data. We consider that this
approach gives an accurate prediction of the likely
pathogenicity associated with each variant; our classifica-
tion of variants almost exactly matches that determined
using a Bayesian approach to classification [28]. The only
exception was the variant A127S; classified as ‘probably
neutral’ using the Baysian model, but presented here as
pathogenic, because of reported evidence of possible func-
tional impairment [29].
The overall frequency of pathogenic mutations deter-
mined by this study (2.2%, 64/2929) is slightly higher
than reported by the GEM study (1.8%, 65/3613) [12]
(Fisher’s Exact p = 0.28 for difference). This is possibly
due to the inclusion of CDKN2A exon 1β in this muta-
tion screen, and the extension of the exon 3 PCR to
cover the common, pathogenic, intron 2 variant c.458-
105A > G [30], neither of which were included in the
GEM screen [12] but which account for 10 carriers
(0.34%) in our sample. Our estimate is lower than a recent
report from Greece, where 5% of cases had mutations
[31], but is equivalent to the 2% frequency of CDKN2A
mutations identified by an Icelandic study [32]. In both
the Greek and Icelandic studies, specific founder muta-
tions dominated the spectrum of mutations observed.
Clearly, founder population effects can influence the over-
all picture; in this study a much more even distribution of
CDKN2A mutations was observed, with no single variant
predominant across the three populations.
We found the prevalence of pathogenic mutations in
CDKN2A was very low (~1%) for cases without a family
history or MPM. The prevalence increased with the
presence of either family history or MPM (~8%), and
was highest for cases with both a family history and
MPM (~25%). This confirms that the most important
predictors of germline CDKN2A mutations in melanoma
cases unselected for family history of the disease are the
same as for those from multiple-case families: namely
the presence of multiple primaries and the strength of
the family history [7].
Earlier age at onset has previously been shown to be
associated with an increased prevalence of CDKN2A
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only for Spanish samples, as was previously reported for
Spanish MPM cases [13]. The observation that for the
Spanish population pathogenic mutations appear to be
slightly more frequent for males than females is also
consistent with previous studies [12,13] in Spain and the
GEM study, which recruited from Europe, the USA and
Australia. We did not observe this sex difference for the
UK and Australia and its significance remains unclear.
Melanoma cases with thinner tumours appeared to
have an increased prevalence of CDKN2A mutations in
the UK sample set in which there was a greater propor-
tion of thicker tumours than in the other two studies (in
part because of an ascertainment choice). It is possible
that this may be a result of people with a family history
of melanoma having their skin checked more regularly
resulting in their melanoma being detected at an earlier
stage, and is consistent with observations that subse-
quent melanomas are thinner than first melanomas [33];
but it may also have been a chance finding. The GEM
study also reported a slightly higher prevalence of
CDKN2A mutations in thinner tumours (p = 0.07) [12].
In the UK there was a suggestion that an increased pro-
portion of individuals with tumours on the trunk car-
ried mutations of CDKN2A. This could indicate that
CDKN2A mutation plays a greater role in tumour de-
velopment at intermittently sun exposed body sites. Be-
cause of limited sample size, the data from Australia
and Spain do not add to this interpretation.
This is the first large series of melanoma cases to report
pathogenic mutations in exon 1β, which uniquely affects
p14ARF, for cases not selected because of their family his-
tory of melanoma or because they have multiple melano-
mas. In the Australian sample one case carried a nonsense
mutation p.W34X, and two cases had mutations that dis-
rupted the splice acceptor site, a known mutation hotspot
for this gene in familial melanoma.
We found no evidence that the common 3′ UTR
variants, c.*29C > G and c.*69C > T were associated with
melanoma susceptibility. Conflicting data have been
published on the significance of the low penetrance
variant p.A148T and melanoma risk [22,23,26]. We ob-
served a significantly increased risk associated with the
p.A148T variant in Australia, and the combined estimate
of the effect of the p.A148T variant across populations
was 1.45 (1.06, 1.98), with no evidence of heterogeneity
across populations (p = 0.56). Further, as all Australian
cases had early onset disease, we divided the other coun-
tries’ data by age (< = 50, vs. >50 years) and found a sig-
nificant difference in the OR by age for the UK sample,
suggesting a stronger effect at younger age (p = 0.001).
Therefore an effect of the p.A148T variant on melanoma
risk, perhaps greater in younger people, is plausible from
our data.Conclusions
Our data suggest that in most clinical settings, testing
for CDKN2A mutations is very unlikely to yield a posi-
tive result (<2% probability) except for melanoma cases
with a strong family history of melanoma, those who
have had three or more primary tumours, and individ-
uals with more than one primary tumour and who also
have other affected family members, where the overall
prevalence of mutations is estimated to be approxi-
mately 25%, 30% and 24% respectively. This provides
additional evidence supporting present advice to clinical
geneticists on genetic testing for melanoma [34].
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